This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Carcinoma in situ of oral cavity and pharynx
CD2_INSITU_OROPHARYNX
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditions
|
519681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
53 |
4. Check minimum number of eventsNone |
53 |
5. Include endpointsNone |
53 |
6. Filter based on genotype QC (FinnGen only) |
53 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- D00
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of oral cavity and pharynx
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of oropharynx, excluding all cancers
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 53 | 18 | 35 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.02 |
| Median age at first event (years) | 64.41 | 70.73 | 61.15 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
23
88
3.85
5.28
3.0
2.4
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
34
174
3.66
4.94
5.0
3.8
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
26
121
3.25
4.25
3.0
2.5
—
—
—
0
0
(3002256) Pathology report gross observation
13
38
4.21
4.22
1.6
1.2
—
—
—
0
0
(40758558) Short blood count panel - Blood
21
89
3.25
3.96
10.7
7.0
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
28
148
2.89
3.51
3.7
2.1
—
—
—
0
0
(4035726)
12
38
3.79
3.46
1.7
1.3
—
—
—
0
0
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
11
33
3.94
3.41
2.0
1.4
—
—
—
0
0
(3001604) Monocytes [#/volume] in Blood
33
194
2.86
3.34
7.9
6.2
e9/l
0.6
0.6
0.43
28
166
(3006315) Basophils [#/volume] in Blood
33
195
2.83
3.29
7.9
6.3
e9/l
0.0
0.0
0.28
28
169
(3019198) Lymphocytes [#/volume] in Blood
33
197
2.79
3.20
8.0
6.3
e9/l
1.8
1.7
0.12
28
172
(3013115) Eosinophils [#/volume] in Blood
33
201
2.70
3.01
8.0
6.4
e9/l
0.2
0.2
0.50
28
174
(3000991) Gas panel - Venous blood
11
36
3.59
3.01
8.9
9.3
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
6
170
0.27
2.84
3.5
3.0
—
—
—
0
0
(3043109) Cytology report of Tissue fine needle aspirate Cyto stain
5
6
9.03
2.81
1.4
1.5
—
—
—
0
0
(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma
33
211
2.49
2.59
9.6
5.5
umol/l
11.2
10.4
0.17
33
199
(3023368) Bacteria identified in Blood by Culture
23
125
2.48
2.56
4.9
4.6
—
—
—
0
0
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
27
159
2.42
2.52
2.2
1.9
pmol/l
95.7
95.0
0.03
13
77
(42870588) Differential panel, method unspecified - Blood
23
127
2.43
2.46
6.4
5.9
—
—
—
0
0
(46235355) HIV 1 and 2 tests - Meaningful Use set
14
61
2.76
2.39
1.2
1.7
—
—
—
0
0
(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count
15
69
2.64
2.31
2.1
2.3
e6/l
0.3
0.8
—
10
38
(3017143) Hepatitis C virus Ab [Presence] in Serum
12
49
2.87
2.30
1.2
1.7
—
—
—
0
0
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
15
70
2.59
2.24
2.1
1.8
—
—
—
0
0
(4010399)
9
31
3.28
2.19
1.6
1.3
—
—
—
0
0
(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma
13
57
2.70
2.18
12.5
10.8
—
—
—
0
0
(3003458) Phosphate [Moles/volume] in Serum or Plasma
14
65
2.57
2.11
4.1
5.9
mmol/l
0.9
1.0
0.91
14
59
(3000494) Fungus identified in Specimen by Culture
12
52
2.69
2.05
2.2
1.5
—
—
—
0
0
(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
24
146
2.18
1.97
2.5
2.2
nmol/l
84.0
76.1
0.54
18
127
(3019832) Treponema pallidum Ab [Presence] in Serum
7
22
3.50
1.95
1.1
1.6
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
11
48
2.63
1.85
1.4
1.6
—
—
—
0
0
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
11
49
2.57
1.78
1.3
1.5
—
—
—
0
0
(3031040) Bacteria [#/volume] in Urine by Automated count
35
254
2.11
1.75
4.6
4.6
—
100.3
—
0
6
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
7
25
3.07
1.71
1.9
1.7
—
—
—
0
0
(3042936) Bacteria identified in Isolate by Culture
13
68
2.21
1.49
2.4
1.7
—
—
—
0
0
(3041096) Erythrocytes [Presence] in Urine by Automated
5
117
0.37
1.49
2.6
3.8
—
—
—
0
0
(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma
9
41
2.43
1.46
2.1
3.2
umol/l
5.3
5.8
—
9
36
(36304419) Bacteria [Presence] in Urine
19
117
1.97
1.44
2.5
2.9
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
16
94
2.01
1.37
1.4
1.4
—
—
—
0
0
(3021879) Hepatitis B virus core Ab [Presence] in Serum
8
35
2.51
1.34
1.3
1.5
—
—
—
0
0
(3022313) Gas panel - Capillary blood
5
18
2.95
1.31
3.8
2.1
—
—
—
0
0
(3030467) Casts [#/volume] in Urine by Automated count
19
121
1.89
1.29
2.7
3.0
e6/l
0.4
0.2
0.20
14
84
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
10
50
2.23
1.26
1.4
1.7
—
—
—
0
0
(3036481) Cortisol [Moles/volume] in Serum or Plasma
7
35
2.15
1.04
2.7
2.1
nmol/l
369.6
360.8
—
7
29
(43054914) Glucose tolerance 2 hours panel - Serum or Plasma
7
35
2.15
1.04
1.1
1.5
—
—
—
0
0
(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood
6
27
2.37
0.97
2.0
2.7
%
2.2
1.4
—
6
27
(3007853) Bacteria identified in Skin by Aerobe culture
8
43
2.01
0.92
2.4
2.0
—
—
—
0
0
(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
6
30
2.12
0.90
1.5
1.3
—
—
—
0
0
(3016293) Bicarbonate [Moles/volume] in Serum or Plasma
6
31
2.05
0.87
12.7
5.7
mmol/l
24.3
25.2
—
6
31
(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
8
47
1.82
0.85
1.3
1.3
—
—
—
0
0
(40762366) Oxygen capacity [Volume Fraction] in Arterial blood
5
23
2.29
0.78
14.6
7.7
—
—
—
0
0
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
5
23
2.29
0.78
1.2
1.8
—
—
—
0
0
(40761535) Cells panel - Urine sediment
7
38
1.97
0.77
4.7
3.1
—
—
—
0
0
(3020891) Body temperature
5
24
2.19
0.77
6.0
4.1
—
—
—
0
0
(3027273) Bicarbonate [Moles/volume] in Venous blood
5
26
2.02
0.72
1.8
2.5
mmol/l
25.5
24.1
—
5
26
(3002032) Base excess in Venous blood by calculation
7
42
1.77
0.72
2.3
3.7
mmol/l
1.0
2.4
—
7
31
(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
5
27
1.94
0.70
2.0
2.6
%
52.8
53.2
—
5
27
(3021589) Normoblasts [#/volume] in Blood
24
188
1.51
0.69
10.0
11.6
e9/l
0.0
0.0
0.00
18
155
(3009343) pH of Capillary blood
5
28
1.87
0.68
4.0
2.4
—
7.4
—
0
6
(3020460) C reactive protein [Mass/volume] in Serum or Plasma
45
406
1.72
0.64
30.0
15.2
mg/l
37.9
21.4
2.11
39
334
(3004119) Hemoglobin [Mass/volume] in Venous blood
6
34
1.86
0.61
2.2
3.0
g/l
130.5
130.6
—
6
34
(3013707) Erythrocyte sedimentation rate by Westergren method
35
302
1.47
0.59
6.3
4.3
mm/h
15.9
12.4
0.69
35
273
(3019225) pH of Specimen
6
38
1.65
0.56
13.8
4.2
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
20
158
1.43
0.52
3.3
3.1
—
—
—
0
0
(3012544) pH of Venous blood
7
46
1.60
0.51
2.3
3.9
—
—
—
0
0
(3018095) Leukocytes [#/volume] in Urine
19
150
1.42
0.50
3.2
3.7
e6/l
8.0
54.9
1.70
12
106
(3011397) Hemoglobin [Presence] in Urine by Test strip
14
104
1.47
0.49
5.3
3.5
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
28
239
1.36
0.46
2.9
2.8
—
—
—
0
0
(3019060) Gas panel - Arterial blood
5
31
1.67
0.44
9.2
3.9
—
—
—
0
0
(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
17
134
1.40
0.44
3.9
2.8
u/l
37.4
29.6
0.42
17
124
(3049717) Cytology report of Urine Cyto stain
0
16
0.00
0.42
0.0
2.8
—
—
—
0
0
(3009542) Hematocrit [Volume Fraction] of Blood
40
364
1.40
0.41
29.2
15.6
%
36.7
40.9
1.08
26
247
(3037121) Protein [Mass/volume] in Urine
0
17
0.00
0.41
0.0
3.3
—
0.1
—
0
10
(3044889) 12 lead EKG panel
33
292
1.34
0.41
5.5
4.1
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
13
165
0.72
0.40
5.0
4.1
—
—
—
0
0
(3013512) EKG study
11
143
0.71
0.38
5.5
4.4
—
—
—
0
0
(3022145) Colonoscopy Study observation
6
41
1.52
0.37
1.5
1.4
—
—
—
0
0
(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma
23
196
1.31
0.36
4.0
4.1
ng/l
15.8
31.4
2.25
17
153
(3026008) Bacteria identified in Urine by Culture
14
111
1.36
0.34
2.9
3.1
—
—
—
0
0
(40761511) CBC panel - Blood by Automated count
46
435
1.43
0.34
22.6
14.1
—
—
—
0
0
(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
30
267
1.28
0.33
4.8
2.9
u/l
68.0
49.1
0.52
30
255
(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
0
11
0.00
0.21
0.0
1.1
—
0.0
—
0
11
(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
0
11
0.00
0.21
0.0
1.1
—
0.0
—
0
11
(3000570) Elastase.pancreatic [Mass/mass] in Stool
0
12
0.00
0.21
0.0
1.5
—
352.1
—
0
5
(40767503) Oxygen content in Capillary blood by calculation
0
13
0.00
0.21
0.0
3.5
—
16.1
—
0
6
(3012110) Lysozyme [Mass/volume] in Serum or Plasma
0
13
0.00
0.21
0.0
1.6
—
11.4
—
0
13
(3037467) Urinalysis macro (dipstick) panel - Urine
30
276
1.20
0.20
4.3
4.7
—
—
—
0
0
(4094501)
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
(3035797) Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis
0
14
0.00
0.20
0.0
1.1
—
0.0
—
0
14
(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
15
172
0.82
0.19
3.0
3.5
%
13.6
21.7
—
5
76
(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum
5
67
0.72
0.18
1.4
1.2
—
10.8
—
0
25
(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
5
43
1.18
0.10
3.6
4.7
ug/l
2.0
13.4
—
5
38
(3002385) Erythrocyte distribution width [Ratio]
33
342
0.91
0.07
33.0
18.5
%
14.2
13.8
0.94
33
333
(3020564) Creatinine [Moles/volume] in Serum or Plasma
43
440
0.88
0.06
34.0
17.5
umol/l
76.9
84.5
1.13
43
440
(40760892) CBC W Ordered Manual Differential panel - Blood
10
90
1.14
0.06
7.3
6.2
—
—
—
0
0
(3015736) pH of Urine
16
169
0.92
0.04
4.8
3.7
—
—
—
0
0
(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)
39
384
1.06
0.01
22.1
15.1
ml/min/173m2
80.3
77.6
0.33
34
312
(40768806) Pleura Pathology biopsy report
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
(3001019) Free T4 and TSH panel - Serum or Plasma
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
(3021901) Oxygen saturation in Capillary blood
0
8
0.00
0.00
0.0
3.1
—
—
—
0
0
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
0
8
0.00
0.00
0.0
2.4
—
—
—
0
0
(3027944) Amphetamines [Presence] in Urine
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma
0
8
0.00
0.00
0.0
2.8
—
15.5
—
0
8
(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(3021125) Hepatitis C virus RNA [Presence] in Serum or Plasma by NAA with probe detection
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3044242) Glucose [Moles/volume] in Arterial blood
0
5
0.00
0.00
0.0
14.8
—
—
—
0
0
(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(3045424) Erythrocytes [Presence] in Urine
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(40763082) Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid by Lactate to pyruvate reaction
0
7
0.00
0.00
0.0
1.1
—
156.9
—
0
7
(3042631) Mycobacterium sp identified in Specimen
0
6
0.00
0.00
0.0
8.3
—
—
—
0
0
(40768795) Lymph node Pathology biopsy report
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3003434) Protein [Mass/volume] in Pleural fluid
0
7
0.00
0.00
0.0
1.1
—
31.9
—
0
7
(3000764) Benzodiazepines [Presence] in Urine
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
(3011288) Drugs identified in Urine by Screen method
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3027008) Opiates [Presence] in Urine
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
(3045788) Cell count panel - Pleural fluid
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3022806) Fractional oxyhemoglobin in Capillary blood
0
7
0.00
0.00
0.0
3.1
—
87.6
—
0
7
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
5
59
0.83
0.00
1.0
1.2
—
—
—
0
0
(3044927) Protein electrophoresis panel - Urine
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(1001926) Buprenorphine [Presence] in Urine by Screen method
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(3016879) Cocaine [Presence] in Urine
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
(3035880) pH of Pleural fluid
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3036782) Glucose [Moles/volume] in Pleural fluid
0
7
0.00
0.00
0.0
1.1
—
6.9
—
0
7
(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3052649) Adenosine deaminase [Enzymatic activity/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.2
—
14.8
—
0
5
(3028300) Cannabinoids [Presence] in Urine
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
(21494815) CD4 cells/100 lymphocytes in Specimen
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_OROPHARYNX – Carcinoma in situ of oral cavity and pharynx
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).